IRIS
BARILLARI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.152
AS - Asia 2.992
EU - Europa 2.666
SA - Sud America 402
AF - Africa 39
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 35.261
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.072
SG - Singapore 1.519
CN - Cina 622
DE - Germania 474
IT - Italia 455
UA - Ucraina 397
RU - Federazione Russa 361
BR - Brasile 337
IE - Irlanda 287
HK - Hong Kong 238
VN - Vietnam 219
FR - Francia 181
GB - Regno Unito 134
PL - Polonia 110
JP - Giappone 93
BD - Bangladesh 79
FI - Finlandia 75
SE - Svezia 49
CA - Canada 47
NL - Olanda 46
IN - India 44
KR - Corea 36
ID - Indonesia 30
AR - Argentina 25
MX - Messico 21
ES - Italia 19
TW - Taiwan 19
AT - Austria 18
TR - Turchia 17
IQ - Iraq 16
ZA - Sudafrica 16
BE - Belgio 12
PH - Filippine 10
CZ - Repubblica Ceca 9
EC - Ecuador 9
PK - Pakistan 8
AL - Albania 7
CL - Cile 7
CO - Colombia 7
AU - Australia 6
TH - Thailandia 6
DK - Danimarca 5
EG - Egitto 5
MA - Marocco 5
UZ - Uzbekistan 5
VE - Venezuela 5
LT - Lituania 4
PE - Perù 4
SA - Arabia Saudita 4
BO - Bolivia 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DZ - Algeria 3
EU - Europa 3
JO - Giordania 3
KE - Kenya 3
LB - Libano 3
MY - Malesia 3
PY - Paraguay 3
RO - Romania 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
BS - Bahamas 2
BY - Bielorussia 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
RS - Serbia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MZ - Mozambico 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
SI - Slovenia 1
SV - El Salvador 1
Totale 35.261
Salva come PNG Salva come JPEG
Città #
Wilmington 7.704
Woodbridge 7.443
Houston 6.817
Singapore 908
Fairfield 619
Chandler 577
Ashburn 445
San Jose 395
Ann Arbor 391
Dearborn 318
Dublin 267
Hong Kong 231
Seattle 231
Cambridge 210
Jacksonville 210
New York 206
Medford 200
Beijing 195
Rome 161
Santa Clara 159
Los Angeles 155
Council Bluffs 127
Chicago 114
Buffalo 94
Lawrence 93
Kraków 88
The Dalles 84
Tokyo 74
Menlo Park 70
Zhengzhou 70
Dallas 68
Ho Chi Minh City 67
Lauterbourg 66
Hanoi 58
San Diego 55
Moscow 52
Salt Lake City 47
Helsinki 35
São Paulo 34
Milan 32
Boardman 29
Phoenix 28
Nuremberg 27
Frankfurt am Main 26
Redondo Beach 25
Tampa 25
Jakarta 22
Elk Grove Village 19
Mülheim 19
Warsaw 19
Chennai 18
Guangzhou 18
Orem 18
Atlanta 17
Redwood City 17
Nanjing 16
Montreal 15
Norwalk 15
Lappeenranta 14
London 14
Shanghai 14
Verona 13
Boston 12
Brussels 12
Dulles 12
Mountain View 12
Brooklyn 11
Detroit 11
Las Vegas 11
Manchester 11
Munich 11
San Francisco 11
Sterling 11
Stockholm 11
Columbus 10
Miami 10
Washington 10
Amsterdam 9
Center 9
Denver 9
Johannesburg 9
Philadelphia 9
Toronto 9
Baghdad 8
Brasília 8
Charlotte 8
Colorado Springs 8
Da Nang 8
Haiphong 8
Kaohsiung 8
Poplar 8
Rio de Janeiro 8
Riverside 8
Wuhan 8
Belo Horizonte 7
Lancaster 7
Mexico City 7
Mumbai 7
Pittsburgh 7
Seoul 7
Totale 29.948
Salva come PNG Salva come JPEG
Nome #
Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma 1.017
Detection of high nerve growth factor serum levels in AIDS-related and -unrelated Kaposi's sarcoma patients 528
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 496
HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia 484
Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. 471
Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses 463
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis 458
The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis 453
HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway 450
A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo 444
The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells 440
Human T-lymphotropic retrovirus infection in Italy 439
Antitumor effects of antiretroviral therapy 435
Fibroblast growth factor-2 and the HIV-1 Tat protein synergize in promoting Bcl-2 expression and preventing endothelial cell apoptosis: implications for the pathogenesis of AIDS-associated Kaposi’s sarcoma. 432
The fibroblast growth factors. 432
Pharmacological management of Kaposi’s sarcoma. 431
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles 430
Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing alpha5beta1 integrin expression and function 427
Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. 422
Inhibition of MMP-9 expression by ritonavir or saquinavir is associated with inactivation of the AKT/Fra-1 pathway in cervical intraepithelial neoplasia cells 422
Pathogenesis of AIDS-associated Kaposi's sarcoma 418
Spindle cells from Acquired Immune Deficiency Syndrome-associated Kaposi’s sarcoma lesions express telomerase activity directly relating to the RNA levels of fibroblast growth factor-2. 417
Another mechanism involved in AIDS-KS progression. 411
Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS 410
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection 406
Entrance of the tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels 403
Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma 397
Angiogenic properties of human immunodeficiency virus type 1 Tat protein 395
HIV protease inhibitors as new treatment options for Kaposi's sarcoma 390
Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16ink4a. 389
Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth 389
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients 387
Treatment of Kaposi's sarcoma--an update 387
HTLV-I and HIV infection in drug addicts in Italy 386
Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via proteasome-independent block of angiogenesis and matrix metalloproteinases. 380
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation 375
The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines 372
Transcription of placenta growth factor type-2 correlates with intratumoral microvessel density in breast carcinomas. 371
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor 369
Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir 367
Basic fibroblast growth factor modifies the interactions between endothelial cells/fibronectin: Implications for progression of AIDS- associated Kaposi's sarcoma 364
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence 364
HTLV-I is endemic in southern Italy: detection of the first infectious cluster in a white population 361
Spindle cells from AIDS-associated Kaposi's sarcoma (KS) lesions express telomerase activity that is enhanced by KS progression factors. 360
Human T-lymphotropic retroviruses: a new member of the family. 357
Basic fibroblast growth factor mediates the growth and angiogenic activity of AIDS-Kaposi’s sarcoma (KS)-derived spindle cells and synergises with HIV-1 Tat protein in inducing KS-like lesions in mice. 356
HIV protease inhibitors block angiogenesis and promote regression of Kaposi’s sarcoma in the nude mouse model. 352
Tat, the transactivator gene of HIV-1, activates the expression of tumor necrosis factor-beta. 352
The use of HAART for biological tumour therapy 349
Release and angiogenic properties of extracellular HIV-1 Tat protein. 346
null 345
Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma 344
Biology of Kaposi's sarcoma 342
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects (TAT domains and pathways for cell growth and transactivation activity). 340
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation independent mechanism which requires binding of Tat to viral particles. 339
Immune activation, rather than immune deficiency, cooperates with HIV infection in the development of AIDS-associated Kaposi’s sarcoma. 338
Biological properties of Human Immunodeficiency Virus type-1 Tat protein: angiogenic effects and adhesive interactions of extracellular Tat. 332
Lymphokines released by activated or HTLV-infected T cells induce growth of normal mesenchymal cells and of cells derived from Kaposi’s sarcoma lesions of AIDS patients. 331
The formation of new blood vessels in Kaposi’s sarcoma. 325
IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis 325
Multicistronic antiangiogenic retroviral vectors for the gene therapy of malignant brain tumors. 323
Role of HIV-1 TAT gene product and of cytokines released by activated immune cells in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 322
PDGF-B as a possible growth factor in AIDS-KS. 322
HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity 321
Interactions between endothelial cells and HIV-1 319
Integrin-mediated uptake of HIV-1 Tat protein by cytokine-activated endothelial cells. 319
HIV-1 Tat protein mimics the effect of extracellular matrix (ECM) protein on vascular cell growth and angiogenesis: implications for AIDS-Kaposi’s sarcoma (AIDS-KS) pathogenesis. 319
Tissue CEA as prognostic indicator in a series of 31 cases of gastric cancer 318
Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin 318
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma 318
Mechanism of paclitaxel activity in Kaposi's sarcoma 315
[Chronic T-lymphocyte lymphatic leukemia. Clinico-pathologic assessment and new epidemiologic data related to cases correlated with HTLV-I in Italy] 315
The angiogenic properties of HIV-I Tat protein are mediated by two different domains. 312
Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines 309
Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis 306
Basic FGF induces lesions in mice resembling KS, and antisense oligonucleotides against this cytokine inhibit the growth and angiogenic activity of KS spindle cells. 306
T-helper phenotype chronic lymphocytic leukaemia and "adult T-cell leukaemia" in Italy. Endemic HTLV-I-related T-cell leukaemias in southern Europe 305
[HIV protease inhibitors for the treatment of Kaposi's sarcoma] 299
Release-uptake of HIV-1 Tat and mechanisms of Tat-induced paracrine biological effects. 298
The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor 297
Cytokines released by activated primary T cells stimulate the growth of AIDS-KS-derived cells and other cells of mesenchymal derivation. 296
Role of cytokines from activated T cells and HIV-1 Tat protein in the pathogenesis of AIDS-associated Kaposi’s sarcoma. 294
HIV-1 Tat protein enhances angiogenesis and Kaposi’s sarcoma development triggered by inflammatory cytokines or bFGF by engaging the avb3 integrin. 291
Immune stimulation and HIV-1 infection have complementary effects in the induction and progression of AIDS-associated Kaposi’s sarcoma via release of cytokines and Tat. 290
Cooperation of HIV-1 Tat protein, inflammatory cytokines or bFGF in the pathogenesis of AIDS-Kaposis’s sarcoma. 273
Inflammatory cytokines increase mesenchymal cell growth and attachment induced by HIV-1 Tat protein and adhesion molecules: implications for AIDS-Kaposi’s sarcoma pathogenesis. 271
Activated peripheral blood lymphocytes produce factors promoting the growth of spindle cells derived from AIDS-associated Kaposi’s sarcoma. 253
About a Possible Impact of Endodontic Infections by Fusobacterium nucleatum or Porphyromonas gingivalis on Oral Carcinogenesis: A Literature Overview 204
Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo 183
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells 182
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 180
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy 168
Infection by high-risk human papillomaviruses, epithelial-to-mesenchymal transition and squamous pre-malignant or malignant lesions of the uterine cervix: a series of chained events? 145
Correlation between pathological data and the RNA expression of p53 or p53-targeted genes in primary invasive ductal breast carcinomas: a preliminary study 128
Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness 125
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma 115
Radioresistance in rhabdomyosarcomas: much more than a question of dose 111
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting 103
Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation 103
Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies 102
Totale 34.393
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.885
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.885
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 0 0 0 0 0 0 27
2021/2022919 19 130 13 63 18 43 48 119 32 54 85 295
2022/20231.326 159 110 100 143 97 276 113 80 123 43 68 14
2023/2024458 49 13 23 17 38 159 20 12 10 38 17 62
2024/20252.777 91 675 324 136 52 143 136 126 225 298 422 149
2025/20264.519 272 155 492 248 390 113 503 474 544 335 828 165
Totale 35.637